publication date: May. 24, 2019
Drugs & Targets Oncopeptides to submit NDA for melflufen in multiple myeloma
After discussions with the FDA, Oncopeptides AB has initiated the preparation for submitting a New Drug Application for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma.
It plans to submit the application in the first quarter of 2020. This could then lead to the first melflufen market approval in the U.S. in 2020.
During the spring, Oncopeptides said it has been working with FDA to explore whether melflufen could be eligible for accelerated approval based on the promising data generated in the ongoing phase II HORIZON clinical trial.
The target indication would be for the treatment of patients with relapsed refractory multiple myeloma whose disease is triple-class refractory (refractory to at least one IMiD, one proteasome inhibitor and one anti-CD38 monoclonal antibody).
In the discussions, the FDA has requested and received all available clinical data at hand for melflufen.
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class of Peptidase Enhanced Cytotoxics, which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers.
Melflufen … Continue reading Oncopeptides to submit NDA for melflufen in multiple myeloma
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.